Skip to main content
Fig. 2 | Clinical Epigenetics

Fig. 2

From: Epigenetic synergy between decitabine and platinum derivatives

Fig. 2

Carboplatin enhanced gene transcription activated by decitabine. a. Carboplatin enhanced GFP mRNA expression in decitabine-treated cells. YB5 cells were treated with decitabine 25 nM, carboplatin 25 μM, and decitabine + carboplatin for 4 days. GFP mRNA was measured by qPCR and normalized to GAPDH. b. The correlation of GFP % measured by flow cytometry with GFP mRNA expression. We treated YB5 cells with a fixed dose of 25 nM decitabine and a variety of doses of carboplatin or cisplatin. The broken line shows fit to a linear regression model. c. Reactivation of expression of genes with methylated promoters in YB5. YB5 cells were treated with decitabine 25 nM, carboplatin 25 μM, and decitabine + carboplatin for 4 days. d. Reactivation of expression of genes with methylated promoters in HL60. HL60 cells were treated with decitabine 200 nM, carboplatin 25 μM, and decitabine + carboplatin for 4 days. mRNA expression was measured by qPCR and normalized to GAPDH. Statistical significance of Bonferroni-corrected t tests is shown by asterisks (**P  < 0.01, ***P < 0.001, ****P < 0.0001)

Back to article page